Long Corridor Asset Management Raises Stake in Oncotherapy Science (4564) to 18.81% | Large Shareholding Report

A large shareholding report (EDINET filing) shows that Long Corridor Asset Management Limited has raised its stake in Oncotherapy Science (4564) to 18.81%. This acquisition was made by a Hong Kong-based activist and event-driven fund. Oncotherapy Science is a biotechnology company engaged in cancer immunotherapy research and development, advancing the development of cancer therapeutics based on its proprietary oncolytic virus technology. The 18.81% stake represents approximately one-fifth of the company's outstanding shares, positioning Long Corridor as a major shareholder.

The acquisition involved an estimated ¥1.3 billion in total investment, with the fund's holding ratio increasing significantly by 14.80 percentage points from its previous disclosure. The filing disclosed on December 10, 2025, demonstrates that Long Corridor has substantially deepened its investment commitment to Oncotherapy Science.

*Speculation: The activist fund's step-by-step increase in shareholding ratio may suggest the potential for constructive engagement with the company regarding its business strategy and corporate value enhancement.